![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Merck’s Lung Cancer Drug Shows Survival Benefit in Study
Merck’s Lung Cancer Drug Shows Survival Benefit in Study
![Merck_logo.jpg](https://www.fdanews.com/ext/resources/test/Drug-Images4/Merck_logo.jpg?t=1576126512&width=430)
October 30, 2015
A Merck study found PD-1 inhibitor Keytruda prolonged life for advanced non-small cell lung cancer patients when compared with standard chemotherapy docetaxel, adding to the case for the medication in an increasingly competitive market.
The company said last week its phase 2/3 trial met primary survival endpoints in patients with PD-1 positive tumors who experienced disease progression after platinum-based chemotherapy. The global study, which began in July 2013, followed 1,034 patients.
Keytruda (pembrolizumab) was approved earlier this month as the first PD-1 inhibitor indicated to treat advanced NSCLC.
Bristol-Myers Squibb’s Opdivo was approved a week after Keytruda for the same disease spectrum, adding on an indication for the non-squamous cell form. That drug will likely consume a larger market portion because of its ability to treat patients regardless of PD-1 expression.
Upcoming Events
-
21Oct